Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem) for adult patients with KRAS-mutated, recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.
Efficacy was evaluated in RAMP-201 (ClinicalTrials.gov Identifier: NCT04625270), a multicenter, open-label trial that included 57 adult patients